Heparin-Induced Thrombocytopenia Clinical Trial
Official title:
Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia
The purpose of the study is to evaluate efficacy and safety of argatroban in the patients with heparin-induced thrombocytopenia (HIT)/ HIT and thrombosis syndrome (HITTS). This multi-center trial covers mainly the patients with cardiovascular diseases. Subjects are included in the trial when they are clinically diagnosed of HIT/HITTS. Initial dose of argatroban is 0.7μg/kg/min, which is about one-third of the approved dose in the US. The reason of the lower initial dose is that the approved dose of argatroban in Japan (for the treatment of ischemic stroke) is about 0.7μg/kg/min and safety of higher doses of the drug are not confirmed. A sub-study of pharmacokinetics is simultaneously conducted to reveal the relationship among the dose, aPTT, and blood drug concentration.
Status | Completed |
Enrollment | 8 |
Est. completion date | September 2006 |
Est. primary completion date | July 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Males of non-pregnant females >=20 and <=80 years of age 2. Those with the diagnosis of HIT or HITTS made by the following diagnostic criteria, or those who have positive results of HIT antibody - diagnostic criteria of HIT - a fall in platelet count to less than 100,000/µL or a 50% decrease in platelets after the initiation of heparin therapy with no apparent explanation other than HIT - diagnostic criteria of HITTS - those who met the diagnosis criteria of HIT - presence of an arterial or venous thrombosis documented by appropriate imaging technique (ultrasound, angiography etc.) or supported by clinical evidence such as a myocardial infarction, stroke, pulmonary embolism, or other clinical indications of vascular occlusion(absence of pulse, cold, cyanotic extremities, etc.) - patients with history of HIT/HITTS with positive test results (HIT antibody or platelet function test) could be enrolled without present thrombocytopenia 3. patients willing and able to give informed consent Exclusion Criteria: 1. any condition which in the investigator's opinion, contraindicated the use of argatroban or endangered the patient if he or she participated in this trial 2. clinically significant or uncontrolled endocrine, renal, pulmonary, gastrointestinal, or psychiatric disorder of sufficient severity that the investigator deemed antithrombotic therapy with argatroban to be contraindicated 3. unexplained aPTT>200% of control at baseline 4. documented coagulation disorder or unexplained bleeding diathesis unrelated to HIT 5. lumbar puncture within the past 7 days 6. known clinical site of bleeding. Patients with a known site of clinical bleeding could be enrolled if the investigator deemed the risk of continued thrombosis outweighed the potential bleeding risk 7. serious liver disfunction 8. females of known or suspected pregnancy 9. breast feeding females 10. participation in other clinical drug trials within the past 30 days 11. history of hypersensitivity to argatroban 12. concomitant use of cimetidine 13. previous participation in this trial |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Sakakibara Memorial Hospital | Fuchu | Tokyo |
Japan | National Hospital Organization Hakodate National Hospital | Hakodate | Hokkaido |
Japan | Tokai University Hospital | Isehara | Kanagawa |
Japan | National Hospital Organization Iwakuni Clinical Center | Iwakuni | Yamaguchi |
Japan | Kobe City General Hospital | Kobe | Hyogo |
Japan | Kobe University Hospital | Kobe | Hyogo |
Japan | Kurume University Hospital | Kurume | Hukuoka |
Japan | Kyoto Second Red Cross Hospital | Kyoto | |
Japan | Kyoto University Hospital | Kyoto | |
Japan | Iwate Medical University Hospital | Morioka | Iwate |
Japan | Nagoya Daini Red Cross Hospital | Nagoya | Aichi |
Japan | Nagoya University Hospital | Nagoya | Aichi |
Japan | National Hospital Organization Nagoya Medical Center | Nagoya | Aichi |
Japan | National Hospital Organization Hokkaido Cancer Center | Sapporo | Hokkaido |
Japan | National Cardiovascular Center | Suita | Osaka |
Japan | Keio University Hospital | Tokyo | |
Japan | National Hospital Organization Tokyo Medical Center | Tokyo | |
Japan | The University of Tokyo Hospital | Tokyo | |
Japan | Mie University Hospital | Tsu | Mie |
Japan | Yamaguchi University Hospital | Ube | Yamaguchi |
Lead Sponsor | Collaborator |
---|---|
Ministry of Health, Labour and Welfare, Japan | Mitsubishi Tanabe Pharma Corporation |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death, new thrombosis, amputation | till 37 days | Yes | |
Secondary | Achievement of anticoagulation therapy | till 37 days | Yes | |
Secondary | Improvement of thrombocytopenia | till 37 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00759083 -
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00456326 -
Heparin-Induced Thrombocytopenia Registry
|
N/A | |
Terminated |
NCT00673439 -
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
|
Phase 2 | |
Active, not recruiting |
NCT00198575 -
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
|
N/A | |
Completed |
NCT00283322 -
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
|
N/A | |
Not yet recruiting |
NCT05586854 -
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06066762 -
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
|
||
Terminated |
NCT03809481 -
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
|
Phase 3 | |
Completed |
NCT05325346 -
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
|
Phase 1 | |
Recruiting |
NCT02717039 -
Pharmacogenomics of Heparin-Induced Thrombocytopenia
|
||
Completed |
NCT02526485 -
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
|
||
Completed |
NCT00748839 -
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
|
N/A | |
Recruiting |
NCT05783895 -
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
|
||
Not yet recruiting |
NCT04782843 -
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
|
||
Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
Terminated |
NCT01598168 -
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
|
Phase 3 | |
Completed |
NCT01654848 -
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
|
N/A | |
Withdrawn |
NCT00603824 -
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
|
Phase 4 |